BiotechTube

INBRX-101/rhAAT-Fc

Phase 1Completed
0 watching 0 views this week💤 Quiet
28
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alpha-1 Antitrypsin Deficiency

Conditions

Alpha-1 Antitrypsin Deficiency, AATD

Trial Timeline

Jul 19, 2019 → Aug 18, 2022

NCT ID
NCT03815396

About INBRX-101/rhAAT-Fc

INBRX-101/rhAAT-Fc is a phase 1 stage product being developed by Inhibrx Biosciences for Alpha-1 Antitrypsin Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT03815396. Target conditions include Alpha-1 Antitrypsin Deficiency, AATD.

Hype Score Breakdown

Clinical
10
Activity
5
Company
5
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT03815396Phase 1Completed

Competing Products

13 competing products in Alpha-1 Antitrypsin Deficiency

See all competitors
ProductCompanyStageHype Score
Drug-Carbamazepine (Tegretol XR) + Carbamazepine (Tegretol XR) PlaceboNovartisPhase 2
52
VX-668 + PlaceboVertex PharmaceuticalsPhase 1
32
VX-864Vertex PharmaceuticalsPhase 2
51
ALN-AAT02 + Placebo + ALN-AAT02Alnylam PharmaceuticalsPhase 1/2
38
ARC-AAT Injection + DiphenhydramineArrowhead PharmaceuticalsPhase 1
30
ARC-AAT InjectionArrowhead PharmaceuticalsPhase 2
49
Alpha-1 MPGrifolsPhase 3
74
Alpha-1 MPGrifolsPhase 3
74
WVE-006WaVe Life SciencesPhase 1
28
WVE-006WaVe Life SciencesPhase 1/2
36
Kamada-AAT for Inhalation, 80mg + Placebo + Kamada-AAT for Inhalation, 160mgKamadaPhase 2
44
KRRO-110Korro BioPhase 1/2
33
Alvelestat (MPH966)Mereo BioPharmaPhase 2
44

Other Products from Inhibrx Biosciences

INBRX-106 + PembrolizumabPhase 2/3
60
INBRX-109 + PlaceboPhase 2
47
Pembrolizumab + INBRX-106Phase 2
47
INBRX-105 - PDL1x41BB antibody + PembrolizumabPhase 1
28
INBRX-109 + Irinotecan + Temozolomide + carboplatin + pemetrexed + Leucovorin + FluorouracilPhase 1
28